A Phase I/IIA, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeated-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants (Part A) and in Study Participants With Moderate-to-Severe Atopic Dermatitis (Part B)
Latest Information Update: 16 Jul 2024
At a glance
- Drugs UCB 9741 (Primary) ; UCB 9741 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors UCB Biopharma
- 28 Jun 2024 Status changed from active, no longer recruiting to completed.
- 14 Jun 2024 This trial has been completed in Bulgaria (End Date: 06 Jun 2024), according to European Clinical Trials Database record.
- 13 Apr 2024 This trial has been suspended in Germany, according to European Clinical Trials Database record.